TriangleNCT02612194 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From date of treatment start to date of death, or censored as described above; assessed for approximately 2 years.
What was measured
Overall survival was defined as the duration from enrollment date to the date of death from any cause. Subjects who were alive or lost to follow-up at the time of the analysis were censored at the last known date they were alive.
Analysis population: Study was designed to evaluate outcomes overall for all enrolled subjects and not separately by molecular cohorts. Efficacy analyses were conducted on the population of subjects who began crizotinib treatment.
Groups in this outcome
Total Enrolled Study Cohort
This group contains all subjects enrolled on the study, who received crizotinib, pooling the subjects in the three molecularly defined cohorts.
| Group | Source count |
|---|---|
| Total Enrolled Study Cohort | 8 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Total Enrolled Study Cohort | 3.1 | Not reported | 0.2 | 6.1 | Not reported |
Source statistical analyses
- ci Lower Limit
- 0.2
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 6.1
- estimate Comment
- The Kaplan Meier method was used to estimate the median OS (in months) for the population. The Greenwood method was used to estimate the confidence limits of the median overall survival.
- group Ids
- OG000
- non Inferiority Comment
- Estimation only
- non Inferiority Type
- OTHER
- param Type
- Median
- param Value
- 3.1
Complete source fields
- analyses
- ci Lower Limit
- 0.2
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 6.1
- estimate Comment
- The Kaplan Meier method was used to estimate the median OS (in months) for the population. The Greenwood method was used to estimate the confidence limits of the median overall survival.
- group Ids
- OG000
- non Inferiority Comment
- Estimation only
- non Inferiority Type
- OTHER
- param Type
- Median
- param Value
- 3.1
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.2
- upper Limit
- 6.1
- value
- 3.1
- denoms
- counts
- group Id
- OG000
- value
- 8
- units
- Participants
- description
- Overall survival was defined as the duration from enrollment date to the date of death from any cause. Subjects who were alive or lost to follow-up at the time of the analysis were censored at the last known date they were alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- This group contains all subjects enrolled on the study, who received crizotinib, pooling the subjects in the three molecularly defined cohorts.
- id
- OG000
- title
- Total Enrolled Study Cohort
- param Type
- MEDIAN
- population Description
- Study was designed to evaluate outcomes overall for all enrolled subjects and not separately by molecular cohorts. Efficacy analyses were conducted on the population of subjects who began crizotinib treatment.
- reporting Status
- POSTED
- time Frame
- From date of treatment start to date of death, or censored as described above; assessed for approximately 2 years.
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice